Form 4: Neogenomics Executive Reports Stock Transactions

Alicia C. Olivo, EVP, GC & Business Development at Neogenomics Inc., reported transactions involving stock options and restricted stock units on May 11, 2026.

Summary

• Alicia C. Olivo, Executive Vice President, General Counsel & Business Development at Neogenomics Inc. (NEO), has filed a Form 4 detailing transactions related to her beneficial ownership of company securities.
• The transactions occurred on May 11, 2026, and involved the acquisition and disposition of common stock, as well as grants of restricted stock units, performance stock units, and stock options.
• Specifically, 3,944 shares of common stock were acquired, and 2,559 shares were disposed of on May 11, 2026.
• Several grants of equity awards were also reported, including restricted stock units, performance stock units, and stock options with various exercise prices and vesting schedules, with grant dates ranging from September 30, 2019, to March 1, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports routine executive stock transactions and grants rather than significant financial performance or strategic shifts.

Positives

• The filing indicates continued equity awards to a key executive, suggesting ongoing incentive alignment with company performance.
• A significant number of stock options and units have been granted, potentially reflecting management's long-term commitment and belief in the company's future growth.

Negatives

• The disposition of 2,559 shares of common stock on May 11, 2026, could be interpreted as a reduction in direct holdings by the executive, although the context of the transaction (e.g., tax withholding) is not specified.
• The exercise prices of some stock options are significantly higher than the current market price (if this were a current filing), which could impact their intrinsic value.

Risks

• The value of granted stock options and performance stock units is contingent on the company's future stock price performance and achievement of specific performance criteria, introducing market and operational risks.
• Vesting schedules for equity awards mean that the executive's full benefit is realized over time, subject to continued employment and performance targets.

Future Outlook

The filing primarily details past and current equity awards and transactions. The future outlook is implicitly tied to the performance of these equity instruments, which are subject to vesting schedules, performance criteria, and market conditions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for executives and directors regarding their holdings and transactions in company stock. This filing provides insight into the compensation structure and executive's stake in Neogenomics Inc., a company operating in the genomics and diagnostics sector.

Stakeholder Impact

• Shareholders: The filing provides transparency into executive compensation and equity holdings, which can influence investor perception of management alignment.
• Employees: The structure of executive compensation, including equity awards, can set a precedent for employee incentive programs.
• Management: The filing details the equity compensation of a key executive, reflecting the company's strategy for retaining and motivating leadership.

Next Steps

• Vesting of granted stock options, restricted stock units, and performance stock units over specified periods.
• Potential future transactions by the reporting person based on vesting and personal financial planning.

Key Dates

Keywords

Form 4, SEC Filing, Neogenomics, NEO, Stock Options, Restricted Stock Units, Performance Stock Units, Beneficial Ownership, Equity Awards, Executive Compensation